{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:40Z","timestamp":1792787260947,"version":"4.5.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Finnish Medical Association","award":["7709"],"award-info":[{"award-number":["7709"]}],"id":[{"id":"https:\/\/ror.org\/04xfxym47","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-00154"],"award-info":[{"award-number":["2021-00154"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2026,3,10]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Comorbid attention-deficit\/hyperactivity disorder (ADHD) increases the burden in bipolar disorder (BD). Concerns about the risk\/benefit balance of ADHD treatment have been raised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to investigate the association between hospital admissions and add-on ADHD medications to antipsychotics and\/or mood-stabilisers (APs\/MSs) compared with AP\/MS alone in BD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individuals with BD prescribed ADHD medications in Sweden during 2006\u20132021 were identified from national registers of inpatient care, specialised outpatient care, sickness absence and disability pension. ADHD treatment was defined as stimulants (mostly methylphenidate and lisdexamfetamine, rarely amphetamine, dexamphetamine) and non-stimulants (atomoxetine, modafinil). Add-on ADHD treatment to concomitant AP\/MS was compared with treatment periods with AP\/MS without ADHD treatment, using within-individual models where individuals acted as their own control. Adjusted HRs (aHRs) and CIs (95% CIs) were calculated for the primary outcome of psychiatric hospitalisation, and for the secondary outcomes: substance-use-related, somatic or mania-related hospitalisations, and all-cause hospitalisation\/mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Altogether, 17\u2009971 individuals (mean age=32.0\u00b111.6 years, males=37.6%, ADHD=88.9%, follow-up=8.9\u00b14.4 years) with BD who used any ADHD treatment were included. compared with the use of AP\/MS alone, add-on stimulant use was related to a lower risk of psychiatric hospitalisations (aHR=0.89, 95% CI 0.85 to 0.93), substance-related hospitalisations (aHR=0.75, 95% CI 0.70 to 0.81) and all-cause hospitalisations\/mortality (aHR=0.90, 95% CI 0.87 to 0.93), but was not associated with increased risk for somatic (aHR=1.00, 95% CI 0.90 to 1.12) or mania-related hospitalisations (aHR=0.93, 95% CI 0.72 to 1.20). Of commonly used specific ADHD medications, add-on lisdexamfetamine (aHR=0.81, 95% CI 0.75 to 0.87) and methylphenidate (aHR=0.92, 95% CI 0.88 to 0.97) were associated with decreased risk of psychiatric hospitalisations while add-on atomoxetine was not. Findings on substance-use-related hospitalisations were significant only for stimulants, specifically lisdexamfetamine (aHR=0.70, 95% CI 0.61 to 0.79) and methylphenidate (aHR=0.80, 95% CI 0.74 to 0.86).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among individuals with BD who received ADHD medications, add-on lisdexamfetamine and methylphenidate were associated with lower risks of psychiatric and substance-use-related hospital admissions, compared with AP\/MS use alone. No significant association was found between ADHD medication use and mania-related hospitalisations or somatic admissions when these medications were used together with AP\/MS. Larger samples are needed to reach adequate statistical power and conclusive findings on atomoxetine, dexamfetamine and modafinil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>The findings of this study suggested that the treatment of comorbid ADHD could be considered after adequate mood-stabilisation in patients with BD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2025-302159","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:25:13Z","timestamp":1773933913000},"page":"e302159","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced risk of cause-specific hospitalisations and all-cause hospitalisation\/mortality during treatment with attention-deficit\/hyperactivity disorder medications in the course of bipolar disorder: a Swedish registry-based within-subject cohort study"],"prefix":"10.1136","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8412-8049","authenticated-orcid":false,"given":"Cagatay","family":"Ermis","sequence":"first","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-3126","authenticated-orcid":false,"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4192-853X","authenticated-orcid":false,"given":"Olivier","family":"Corbeil","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute (OHRI), Clinical Epidemiology Program, SCIENCES Lab, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Department of Pharmacy, Mental Health University Institute of Quebec, Qu\u00e9bec City, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6030-0249","authenticated-orcid":false,"given":"Johannes","family":"Lieslehto","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Stockholm County, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[{"name":"Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U","family":"Correll","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellenor","family":"Mittendorfer-Rutz","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Stockholm County, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2026091806102444000_29.1.e302159.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.01.017"},{"key":"2026091806102444000_29.1.e302159.2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/00048674221106669","article-title":"Clinical correlates of comorbid attention deficit hyperactivity disorder in adults suffering from bipolar disorder: A meta-analysis","volume":"57","author":"Bartoli","year":"2023","journal-title":"Aust N Z J Psychiatry"},{"key":"2026091806102444000_29.1.e302159.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.06.036"},{"key":"2026091806102444000_29.1.e302159.4","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1517\/14656566.2015.1079620","article-title":"The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder","volume":"16","author":"Perugi","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2026091806102444000_29.1.e302159.5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/104012371202400104","article-title":"The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit\/hyperactivity disorder","volume":"24","author":"Bond","year":"2012","journal-title":"Ann Clin Psychiatry"},{"key":"2026091806102444000_29.1.e302159.6","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12609"},{"key":"2026091806102444000_29.1.e302159.7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S2215-0366(23)00199-2","article-title":"Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis","volume":"10","author":"Yildiz","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"2026091806102444000_29.1.e302159.8","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-017-0758-x","article-title":"Use of Stimulants in Bipolar Disorder","volume":"19","author":"Perugi","year":"2017","journal-title":"Curr Psychiatry Rep"},{"key":"2026091806102444000_29.1.e302159.9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bdi.13414","article-title":"Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force","volume":"26","author":"Miskowiak","year":"2024","journal-title":"Bipolar Disord"},{"key":"2026091806102444000_29.1.e302159.10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/104012371102300107","article-title":"Cardiovascular morbidity and mortality in bipolar disorder","volume":"23","author":"Weiner","year":"2011","journal-title":"Ann Clin Psychiatry"},{"key":"2026091806102444000_29.1.e302159.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02109-9"},{"key":"2026091806102444000_29.1.e302159.12","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13254"},{"key":"2026091806102444000_29.1.e302159.13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.psychres.2017.02.067","article-title":"Substance abuse in patients with bipolar disorder: A systematic review and meta-analysis","volume":"253","author":"Messer","year":"2017","journal-title":"Psychiatry Res"},{"key":"2026091806102444000_29.1.e302159.14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S2215-0366(15)00207-2","article-title":"Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study","volume":"2","author":"Hjorth\u00f8j","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"2026091806102444000_29.1.e302159.15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/add.16347","article-title":"Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"119","author":"Sharafi","year":"2024","journal-title":"Addiction"},{"key":"2026091806102444000_29.1.e302159.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05563-3"},{"key":"2026091806102444000_29.1.e302159.17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamapsychiatry.2022.3788","article-title":"Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13\u202f965 Patients","volume":"80","author":"Hartikainen","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"2026091806102444000_29.1.e302159.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813751"},{"key":"2026091806102444000_29.1.e302159.19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16040467"},{"key":"2026091806102444000_29.1.e302159.20","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1176\/appi.ajp.20230329","article-title":"Risk of Incident Psychosis and Mania With Prescription Amphetamines","volume":"181","author":"Moran","year":"2024","journal-title":"Am J Psychiatry"},{"key":"2026091806102444000_29.1.e302159.21","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1080\/14656566.2023.2224920","article-title":"A systematic review of pharmacotherapy for attention-deficit\/hyperactivity disorder in children and adolescents with bipolar disorders","volume":"24","author":"Pouchon","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"2026091806102444000_29.1.e302159.22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/JCP.0000000000001631","article-title":"Risk of Mania After Methylphenidate in Patients With Bipolar Disorder","volume":"43","author":"Jefsen","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"2026091806102444000_29.1.e302159.23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.2859","article-title":"Attention-Deficit\/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes","volume":"7","author":"Taipale","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026091806102444000_29.1.e302159.24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2215-0366(24)00411-5","article-title":"Real-world effectiveness of pharmacological maintenance treatment of bipolar depression: a within-subject analysis in a Swedish nationwide cohort","volume":"12","author":"Ermis","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026091806102444000_29.1.e302159.25","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology . Guidelines for ATC classification and DDD assignment 2024. Oslo, Norway, 2023."},{"key":"2026091806102444000_29.1.e302159.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12911-015-0140-z","article-title":"From prescription drug purchases to drug use periods \u2013 a second generation method (PRE2DUP)","volume":"15","author":"Tanskanen","year":"2015","journal-title":"BMC Med Inform Decis Mak"},{"key":"2026091806102444000_29.1.e302159.27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/0004867421998779","article-title":"Use of methylphenidate and the incidence of intentional self-harm or suicide attempts among individuals with schizophrenia, bipolar disorder and personality disorder","volume":"55","author":"Rohde","year":"2021","journal-title":"Aust N Z J Psychiatry"},{"key":"2026091806102444000_29.1.e302159.28","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bdi.13440","article-title":"Prescribed psychostimulants and other pro-cognitive medications in bipolar disorder: A systematic review and meta-analysis of recurrence of manic symptoms","volume":"26","author":"Chiorean","year":"2024","journal-title":"Bipolar Disord"},{"key":"2026091806102444000_29.1.e302159.29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/jamapsychiatry.2023.4294","article-title":"Attention-Deficit\/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases","volume":"81","author":"Zhang","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"2026091806102444000_29.1.e302159.30","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12164"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2025-302159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:10:54Z","timestamp":1789737054000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2025-302159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,19]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjment-2025-302159"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2025-302159","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}